Project Grant R01DK142175
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $388,750 on April 23, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the structural and functional mechanisms of podocin in glomerular membrane organization and kidney disease. The research applies detergent-free, vesicle-based cryo-electron microscopy to determine the full-length structure of podocin at near-atomic resolution...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Trustees of Columbia University in the City of New York $123,375 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct structure-guided research aimed at preventing polymyxin-induced acute kidney injury. The project will characterize the interaction between polymyxin B and the endocytic receptor LRP2/megalin using cross-linking mass spectrometry...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $821,816 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the microbial contributors to hematopoiesis and the mechanisms by which commensal intestinal bacteria maintain normal blood cell production. The research interrogates how depletion of commensal bacteria causes cytopenias (low peripheral blood counts) in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $165,104 on February 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support basic research on mechanisms of HDL-mediated lipopolysaccharide neutralization and intestinal HDL transport into portal venous circulation. The recipient will characterize the protein and lipid constituents of LPS-neutralizing complexes using proteomics and...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Washington University a Project Grant totaling $1,491,303 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the period September 5, 2025, through September 4, 2029. This award supports basic biomedical research investigating the molecular mechanisms that drive progression from acute kidney injury (AKI) to chronic kidney...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $614,186 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of intestinal microbiota and immune cell trafficking in acute kidney injury repair. The research examines mechanistic pathways by which immune cells mediate recovery from severe acute kidney injury via microbiome-mediated migration from the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $795,317 to the Research Institute At Nationwide Children's Hospital on August 19, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the roles of RNase3, RNase6, and ribonuclease inhibitor in bacterial urinary tract infection. The research uses engineered transgenic mice to determine how RNase3 and RNase6, phagocyte-derived antimicrobial peptides in the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $192,763 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), a Project Grant supporting basic and clinical biomedical research that improves understanding of disease mechanisms and leads to improved prevention, diagnosis, and treatment. The award funds a prospective nested cohort study investigating mechanisms of kidney...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $449,337 to the University of Wisconsin System on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how tuft cells—rare chemosensory epithelial cells—control microbiome-dependent inflammation in extrahepatic biliary tissues. The recipient, University of Wisconsin–Madison, will conduct research demonstrating that the extrahepatic biliary tree...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $127,206 to The Washington University on April 5, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research investigates Prevotella copri-mediated effects of dietary glycan supplementation on microbial community and host metabolism in the context of treating childhood undernutrition. The work builds on clinical trial evidence that microbiota-directed complementary...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $547,349 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the mechanisms of E. coli alpha-hemolysin toxicity to renal epithelium. The project, R01DK142175, examines how uropathogenic E. coli (UPEC) employs the secreted toxin alpha-hemolysin (HlYA) to damage kidney tissue during urinary tract infections, particularly pyelonephritis. Recent preliminary findings identified that HlYA cytotoxicity to renal epithelial cells requires clathrin-mediated endocytosis and the low-density lipoprotein receptor (LDLR). The funded research will test the hypothesis that UPEC HlYA binds LDLR, is internalized via clathrin-mediated endocytosis, subsequently pores lysosomes, and causes lethal mitochondrial injury in kidney cells. The work will interrogate the cellular and molecular pathways underlying this mechanism of bacterial toxicity. Performance occurs at The Washington University, St. Louis, Missouri, with period of performance from September 1, 2026, through May 31, 2031. The funding is structured as a Project Grant, the standard NIH competitive research award mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $547.3k | 8/26/26 |